Shanxi Zhendong Pharmaceutical Co.,Ltd (300158.SZ)
CNY 3.77
(3.86%)
CNY 3.77
(3.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 94.75 Million CNY | 23.55% |
| 2022 | 157.99 Million CNY | -97.5% |
| 2021 | 3.26 Billion CNY | 515.08% |
| 2020 | 545.59 Million CNY | 45.64% |
| 2019 | 333.73 Million CNY | 59.57% |
| 2018 | 100 Million CNY | -59.56% |
| 2017 | 459.37 Million CNY | 37.19% |
| 2016 | 350.85 Million CNY | 86.28% |
| 2015 | 158.97 Million CNY | 34.29% |
| 2014 | 154.34 Million CNY | -3.74% |
| 2013 | 129.48 Million CNY | -5.52% |
| 2012 | 163.18 Million CNY | 4.26% |
| 2011 | 153.45 Million CNY | 19.82% |
| 2010 | 130.28 Million CNY | 28.11% |
| 2009 | 109.52 Million CNY | 9.68% |
| 2008 | 98.16 Million CNY | 38.19% |
| 2007 | 71.23 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 17.4 Million CNY | 297.84% |
| 2024 Q2 | 29.73 Million CNY | -64.86% |
| 2024 Q3 | 12.11 Million CNY | 10.21% |
| 2023 Q3 | -12.75 Million CNY | -124.11% |
| 2023 Q2 | 52.9 Million CNY | 847.4% |
| 2023 Q4 | -65.67 Million CNY | -414.78% |
| 2023 Q1 | 5.58 Million CNY | 104.46% |
| 2023 FY | - CNY | 23.55% |
| 2022 Q1 | 27.07 Million CNY | -99.02% |
| 2022 Q2 | 39.85 Million CNY | 47.22% |
| 2022 FY | - CNY | -97.5% |
| 2022 Q4 | -125.19 Million CNY | -958.22% |
| 2022 Q3 | 14.58 Million CNY | -63.4% |
| 2021 Q1 | 124.74 Million CNY | 57.45% |
| 2021 Q3 | 116.93 Million CNY | -27.41% |
| 2021 FY | - CNY | 515.08% |
| 2021 Q4 | 2.76 Billion CNY | 2261.0% |
| 2021 Q2 | 161.08 Million CNY | 29.13% |
| 2020 FY | - CNY | 45.64% |
| 2020 Q2 | 89.18 Million CNY | 8.2% |
| 2020 Q1 | 82.42 Million CNY | 267.81% |
| 2020 Q3 | 117.77 Million CNY | 32.07% |
| 2020 Q4 | 79.23 Million CNY | -32.73% |
| 2019 Q1 | 76.28 Million CNY | 5766.49% |
| 2019 FY | - CNY | 59.57% |
| 2019 Q4 | 22.4 Million CNY | -67.76% |
| 2019 Q3 | 69.51 Million CNY | -15.98% |
| 2019 Q2 | 82.73 Million CNY | 8.47% |
| 2018 Q3 | -13.96 Million CNY | -119.37% |
| 2018 Q1 | 56.93 Million CNY | -59.89% |
| 2018 Q4 | 1.3 Million CNY | 109.31% |
| 2018 Q2 | 72.07 Million CNY | 26.6% |
| 2018 FY | - CNY | -59.56% |
| 2017 Q4 | 141.92 Million CNY | 38.34% |
| 2017 Q2 | 147.66 Million CNY | 101.81% |
| 2017 FY | - CNY | 37.19% |
| 2017 Q1 | 73.16 Million CNY | -47.27% |
| 2017 Q3 | 102.58 Million CNY | -30.52% |
| 2016 Q4 | 138.76 Million CNY | 56.64% |
| 2016 Q1 | 23.6 Million CNY | -63.47% |
| 2016 FY | - CNY | 86.28% |
| 2016 Q2 | 47.21 Million CNY | 100.07% |
| 2016 Q3 | 88.58 Million CNY | 87.61% |
| 2015 Q2 | 39.7 Million CNY | 109.72% |
| 2015 FY | - CNY | 34.29% |
| 2015 Q4 | 64.61 Million CNY | 218.01% |
| 2015 Q3 | 20.31 Million CNY | -48.83% |
| 2015 Q1 | 18.93 Million CNY | -12.96% |
| 2014 Q2 | 41.12 Million CNY | 62.7% |
| 2014 Q4 | 21.74 Million CNY | 3.95% |
| 2014 Q3 | 20.92 Million CNY | -49.13% |
| 2014 FY | - CNY | -3.74% |
| 2014 Q1 | 25.27 Million CNY | -27.12% |
| 2013 Q2 | 30.6 Million CNY | -7.92% |
| 2013 Q3 | 28.46 Million CNY | -6.99% |
| 2013 Q4 | 34.68 Million CNY | 21.83% |
| 2013 FY | - CNY | -5.52% |
| 2013 Q1 | 33.23 Million CNY | -51.26% |
| 2012 Q2 | 14.13 Million CNY | -56.03% |
| 2012 Q1 | 32.13 Million CNY | -40.91% |
| 2012 FY | - CNY | 4.26% |
| 2012 Q4 | 68.18 Million CNY | 112.53% |
| 2012 Q3 | 32.08 Million CNY | 127.06% |
| 2011 Q4 | 54.38 Million CNY | 64.19% |
| 2011 FY | - CNY | 19.82% |
| 2011 Q1 | 20.86 Million CNY | -34.93% |
| 2011 Q2 | 51.65 Million CNY | 147.53% |
| 2011 Q3 | 33.12 Million CNY | -35.87% |
| 2010 Q4 | 32.07 Million CNY | -22.4% |
| 2010 FY | - CNY | 28.11% |
| 2010 Q1 | 16.78 Million CNY | -42.73% |
| 2010 Q2 | 35.09 Million CNY | 109.06% |
| 2010 Q3 | 41.33 Million CNY | 17.75% |
| 2009 FY | - CNY | 9.68% |
| 2009 Q4 | 29.31 Million CNY | 11.5% |
| 2009 Q3 | 26.29 Million CNY | 0.0% |
| 2008 FY | - CNY | 38.19% |
| 2007 FY | - CNY | 0.0% |